Janssen pulls out of deal with Bavarian Nordic

9 May 2022

Denmark-based vaccine developer Bavarian Nordic (OMX: BAVA) saw its share drop more than 9% to 120.55 kroner by close of trading today on news that Johnson & Johnson (NYSE: JNJ) subsidiary Janssen had terminated certain collaboration and license agreements.

The accord was aimed at leveraging Bavarian Nordic’s MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) technology to develop potential vaccines against the hepatitis B virus and human papillomaviruses (HPV).

In its press release, Janssen said it remains committed to its strong collaboration with Bavarian Nordic in the quest to prevent and cure infectious diseases – with collaborations in HIV and Ebola still ongoing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK